Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 25, Issue 1, 2013, Pages 69-76

  El Mezayen, Hatem A ^a   Toson, El Shahat A ^b   Shiha, Gamal E ^c  

^a Helwan University   (Egypt)

^b Damietta University   (Egypt)

^c MANSOURA UNIVERSITY   (Egypt)

Author keywords

Blood; Ferritin; Fibrosis; Hepatitis C virus; Hyaluronic acid; Liver

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BETA GLUCURONIDASE; ENZYME; FERRITIN; GLUCOSAMINE; HYALURONIC ACID; N ACETYL BETA GLUCOSAMINIDASE;

ADULT; ARTICLE; DISEASE SEVERITY; EGYPT; ENZYME BLOOD LEVEL; FEMALE; FERRITIN BLOOD LEVEL; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM;

ACETYLGLUCOSAMINIDASE; ADULT; ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; BIOPSY; DECISION SUPPORT TECHNIQUES; DISCRIMINANT ANALYSIS; EGYPT; FEMALE; FERRITINS; GLUCOSAMINE; GLUCURONIDASE; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; HYALURONOGLUCOSAMINIDASE; LINEAR MODELS; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; UNNECESSARY PROCEDURES;

EID: 84870908202     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3283594924     Document Type: Article

References (53)

1. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 (Suppl 1):9-16.
2. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36:S152-S160.
3. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500.
4. Watanabe N, Aizaki H, Matsuura T, Kojima S, Wakita T, Suzuki T. Hepatitis C virus RNA replication in human stellate cells regulates gene expression of extracellular matrix-related molecules. Biochem Biophys Res Commun 2011; 407:135-140.
5. Weissmann B, Meyer K, Sampson P, Linker A. Isolation of oligosaccharides enzymatically produced from hyaluronic acid. J Biol Chem 1954; 208: 417-429.
6. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002; 21:25-29.
7. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995; 22:22-26.
8. Ramadori G, Zohrens G, Manns M, Rieder H, Dienes HP, Hess G, et al. Serum hyaluronate and type III procollagen aminoterminal propeptide concentration in chronic liver disease. Relationship to cirrhosis and disease activity. Eur J Clin Invest 1991; 21:323-330.
9. Masamune H, Aizawa I. Biochemical studies on carbohydrates. 198. Spectrophotometric determination of glucuronic acid in co-presence of galacturonic acid. Tohoku J Exp Med 1957; 65:359-365.
10. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
11. Aronson NN Jr., Davidson EA. Lysosomal hyaluronidase from rat liver. II. Properties. J Biol Chem 1967; 242:441-444.
12. George J, Stern R. Serum hyaluronan and hyaluronidase: very early markers of toxic liver injury. Clin Chim Acta 2004; 348:189-197.
13. Goren MP, Wright RK, Horowitz ME, Crom WR, Meyer WH. Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate. J Clin Oncol 1987; 5: 804-810.
14. Elsafi ME, Hultberg B, Isaksson A, Hagerstrand I, Prytz H, Stenram U. Lysosomes and human liver disease: a biochemical and immunohistochemical study of beta-hexosaminidase. Eur J Clin Chem Clin Biochem 1994; 32:669-673.
15. Weismuller TJ, Kirchner GI, Scherer MN, Negm AA, Schnitzbauer AA, Lehner F, et al. Serum ferritin concentration and transferrin saturation before liver transplantation predict decreased long-term recipient survival. Hepatology 2011; 54:2114-2124.
16. Lange CM, Kutalik Z, Morikawa K, Bibert S, Cerny A, Dollenmaier G, et al. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy. Hepatology 2011; 55:1038-1047.
17. Persico M, Palmentieri B, Vecchione R, Torella R, de SI. Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol 2002; 97:491-492.
18. Hutterer F. Degradation of mucopolysaccharides by hepatic lysosomes. Biochim Biophys Acta 1966; 115:312-319.
19. Pugh D, Leaback DH, Walker PG. Studies on glucosaminidase; N-acetylbeta- glucosaminidase in rat kidney. Biochem J 1957; 65:464-469.
20. Goldbarg JA, Pineda EP, Banks BM, Rutenburg AM. A method for the colorimetric determination of beta-glucuronidase in urine, serum, and tissue; assay of enzymatic activity in health and disease. Gastroenterology 1959; 36:193-201.
21. Boas NF. Method for the determination of hexosamines in tissues. J Biol Chem 1953; 204:553-563.
22. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993; 39: 561-577.
23. Huguet J, Castineiras MJ, Fuentes-Arderiu X. Diagnostic accuracy evaluation using roc curve analysis. Scand J Clin Lab Invest 1993; 53:693-699.
24. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus interferon study group. J Gastroenterol Hepatol 2000; 15:945-951.
25. Afdhal NH. Diagnosing fibrosis in hepatitis C: is the pendulum swinging from biopsy to blood tests? Hepatology 2003; 37:972-974.
26. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998; 28:439-446.
27. Oh S, Afdhal NH. Hepatic fibrosis: are any of the serum markers useful? Curr Gastroenterol Rep 2001; 3:12-18.
28. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481.
29. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36:986-992.
30. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
31. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. M: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-1325.
32. Berenguer J, Bellon JM, Miralles P, Alvarez E, Sanchez-Conde M, Cosin J, et al. Identification of liver fibrosis in HIV/HCV-coinfected patients using a simple predictive model based on routine laboratory data. J Viral Hepat 2007; 14:859-869.
33. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCVassociated liver disease. World J Gastroenterol 2005; 11:476-481.
34. Resino S, Bellon JM, Asensio C, Micheloud D, Miralles P, Vargas A, et al. Can serum hyaluronic acid replace simple non-invasive indexes to predict liver fibrosis in HIV/hepatitis C coinfected patients? BMC Infect Dis 2010; 10:244.
35. Attallah AM, Toson el SA, El-Waseef AM, Abo-Seif MA, Omran MM, Shiha GE. Discriminant function based on hyaluronic acid and its degrading enzymes and degradation products for differentiating cirrhotic from noncirrhotic liver diseased patients in chronic HCV infection. Clin Chim Acta 2006; 369:66-72.
36. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003; 18:253-257.
37. Nir I. Determination of glucuronic acid by naphthoresorcinol. Anal Biochem 1964; 8:20-23.
38. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E. Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001; 47:1696-1700.
39. Melen K, Hultberg B, Hagerstrand I, Isaksson A, Joelsson B, Bengmark S. Lysosomal enzymes in plasma, liver and spleen from rats with carbon tetrachloride-induced liver cirrhosis. Enzyme 1985; 33:84-88.
40. Hultberg B, Hagerstrand I, Isaksson A, Joelsson B, Melen K, Elsafi M. Source of increased serum beta-hexosaminidase in rat liver cirrhosis. Enzyme 1988; 40:18-24.
41. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007; 22:1886-1893.
42. Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011; 31:730-739.
43. Moon JH, Park SH, Oh KC, Jung JO, Shin WG, Kim JP, et al. Association of hepatic iron deposition and serum iron indices with hepatic inflammation and fibrosis stage in nonalcoholic fatty liver disease. Korean J Gastroenterol 2006; 47:432-439.
44. Griffiths WJ, Kelly AL, Smith SJ, Cox TM. Localization of iron transport and regulatory proteins in human cells. QJM 2000; 93:575-587.
45. Fujita N, Nakanishi M, Mukai J, Naito Y, Ichida T, Kaito M, et al. Identification of treatment efficacy-related host factors in chronic hepatitis C by proteinchip serum analysis. Mol Med 2010; 17:70-78.
46. Bresgen N, Ohlenschlager I, Fiedler B, Wacht N, Zach S, Dunkelmann B, et al. Ferritin - a mediator of apoptosis? J Cell Physiol 2007; 212:157-164.
47. Ruddell RG, Hoang-Le D, Barwood JM, Rutherford PS, Piva TJ, Watters DJ, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology 2009; 49:887-900.
48. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51:1683-1691.
49. Tangkijvanich P, Kongtawelert P, Pothacharoen P, Mahachai V, Suwangool P, Poovorawan Y. Serum hyaluronan: a marker of liver fibrosis in patients with chronic liver disease. Asian Pac J Allergy Immunol 2003; 21:115-120.
50. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005; 41:1376-1382.
51. Giannini E, Botta F, Testa E, Romagnoli P, Polegato S, Malfatti F, et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am J Gastroenterol 2002; 97:2855-2860.
52. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis c infection. Clin Chem 2005; 51:1867-1873.
53. Benlloch S, Berenguer M, Prieto M, Rayon JM, Aguilera V, Berenguer J. Prediction of fibrosis in HCV-infected liver transplant recipients with a simple noninvasive index. Liver Transpl 2005; 11:456-462.